Your browser doesn't support javascript.
loading
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
Risbridger, Gail P; Clark, Ashlee K; Porter, Laura H; Toivanen, Roxanne; Bakshi, Andrew; Lister, Natalie L; Pook, David; Pezaro, Carmel J; Sandhu, Shahneen; Keerthikumar, Shivakumar; Quezada Urban, Rosalia; Papargiris, Melissa; Kraska, Jenna; Madsen, Heather B; Wang, Hong; Richards, Michelle G; Niranjan, Birunthi; O'Dea, Samantha; Teng, Linda; Wheelahan, William; Li, Zhuoer; Choo, Nicholas; Ouyang, John F; Thorne, Heather; Devereux, Lisa; Hicks, Rodney J; Sengupta, Shomik; Harewood, Laurence; Iddawala, Mahesh; Azad, Arun A; Goad, Jeremy; Grummet, Jeremy; Kourambas, John; Kwan, Edmond M; Moon, Daniel; Murphy, Declan G; Pedersen, John; Clouston, David; Norden, Sam; Ryan, Andrew; Furic, Luc; Goode, David L; Frydenberg, Mark; Lawrence, Mitchell G; Taylor, Renea A.
Afiliação
  • Risbridger GP; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia. gail.risbridger@monash.edu.
  • Clark AK; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. gail.risbridger@monash.edu.
  • Porter LH; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Toivanen R; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Bakshi A; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Lister NL; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Pook D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Pezaro CJ; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Sandhu S; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Keerthikumar S; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Quezada Urban R; Computational Cancer Biology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Papargiris M; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Kraska J; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Madsen HB; Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
  • Wang H; Department of Medical Oncology, Monash Health, Clayton, VIC, Australia.
  • Richards MG; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Niranjan B; Eastern Health and Monash University Eastern Health Clinical School, Box Hill, VIC, Australia.
  • O'Dea S; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England.
  • Teng L; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Wheelahan W; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Li Z; Cancer Tissue Collection After Death (CASCADE) Program, Melbourne, VIC, Australia.
  • Choo N; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Ouyang JF; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Thorne H; Computational Cancer Biology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Devereux L; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Hicks RJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.
  • Sengupta S; Computational Cancer Biology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Harewood L; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Iddawala M; Australian Prostate Cancer Bioresource, VIC Node, Monash University, Clayton, VIC, Australia.
  • Azad AA; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Goad J; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Grummet J; Australian Prostate Cancer Bioresource, VIC Node, Monash University, Clayton, VIC, Australia.
  • Kourambas J; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Kwan EM; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Moon D; Australian Prostate Cancer Bioresource, VIC Node, Monash University, Clayton, VIC, Australia.
  • Murphy DG; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Pedersen J; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Clouston D; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Norden S; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Ryan A; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Furic L; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Goode DL; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Physiology, Monash University, Clayton, VIC, Australia.
  • Frydenberg M; Prostate Cancer Research Group, Monash Biomedicine Discovery Institute, Cancer Program, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.
  • Lawrence MG; Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore.
  • Taylor RA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Nat Commun ; 12(1): 5049, 2021 08 19.
Article em En | MEDLINE | ID: mdl-34413304
ABSTRACT
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Organoides / Avaliação Pré-Clínica de Medicamentos Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Organoides / Avaliação Pré-Clínica de Medicamentos Idioma: En Ano de publicação: 2021 Tipo de documento: Article